Gilead gets Biktarvy boost in comparison with Triumeq
Competition between Gilead Sciences (Nasdaq: GILD) and the GlaxoSmithKline (LSE: GSK) subsidiary ViiV Healthcare in the HIV space remains intense, with the US biotech presenting 96-week results from a Phase III trial of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide tablets).
In the ongoing study of treatment-naïve adults with HIV-1, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine, which is marketed by ViiV as Triumeq.
Importantly, Biktarvy was shown to have less nausea with a similar bone and renal safety profile to the comparator through 96 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze